Abstract
Biologics have revolutionised the management of immune-mediated inflammatory disorders, and their growing use has resulted in increasing numbers of these patients presenting in oral surgery settings. While the efficacy of biologics has been well established, they are associated with numerous adverse effects. Several professional bodies have published recommendations on perioperative management of these agents to reduce complications. Currently no specific dental or oral surgery guidance exists. The aim of this paper is to review the current literature and guidance regarding the use of biologics in the perioperative period.
Subject
Periodontics,Dentistry (miscellaneous),Oral Surgery
Reference45 articles.
1. Food US, Administration D. Commissioner Scott Gottlieb. The FDA's Biosimilars Action Plan 2018. Brookings Institution, Washington, DC. https://www.fda.gov/news-events/press-announcements/remarks-fda-commissioner-scott-gottlieb-md-prepared-delivery-brookings-institution-release-fdas [Accessibility verified November 14, 2021]
2. Biologics in oral medicine: principles of use and practical considerations
3. Infections Related to Biologics
4. Should biologic agents be stopped before surgery for inflammatory bowel disease?
5. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update